半乳糖凝集素在肝脏疾病中的作用：一项系统评价与荟萃分析。
Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis.
作者信息
An Yang, Xu Shixue, Liu Yiting, Xu Xiangbo, Philips Cyriac Abby, Chen Jiang, Méndez-Sánchez Nahum, Guo Xiaozhong, Qi Xingshun
机构信息
Meta-Analysis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China.
Postgraduate College, Shenyang Pharmaceutical University, Shenyang, China.
出版信息
Front Med (Lausanne). 2021 Oct 27;8:744518. doi: 10.3389/fmed.2021.744518. eCollection 2021.
Galectins, a family of β-galactoside-binding proteins, are related to the development and progression of various human diseases such as cancer, heart failure, and chronic kidney disease. However, its role in liver diseases is unclear. The PubMed, Embase, and Cochrane Library databases were searched. Hazard ratios (HRs), odds ratios (ORs), and mean differences (MDs) with 95% CIs were pooled to evaluate the association of the galectins with the outcomes and risk of liver diseases by a random effects model. Thirty three studies involving 43 cohorts and 4,168 patients with liver diseases were included. In the patients with hepatocellular carcinoma (HCC), high expression of galectin-1 and -3 in the tissues was significantly associated with worse overall survival (galectin-1: HR = 1.94, 95% CI = 1.61-2.34, < 0.001; galectin-3: HR = 3.29, 95% CI = 1.62-6.68, < 0.001) and positive vascular invasion (galectin-1: OR = 1.74, 95% CI = 1.18-2.58, = 0.005; galectin-3: OR = 2.98, 95% CI = 1.58-5.60, = 0.001); but, high expression of galectin-4 and -9 in the tissues was significantly associated with better overall survival (galectin-4: HR = 0.53, 95% CI = 0.36-0.79, = 0.002; galectin-9: HR = 0.56, 95% CI = 0.44-0.71, < 0.001) and negative vascular invasion (galectin-4: OR = 0.36, 95% CI = 0.19-0.72, = 0.003; galectin-9: OR = 0.60, 95% CI = 0.37-0.97, = 0.037). Serum galectin-3 level was significantly higher in HCC (MD = 3.06, 95% CI = 1.79-4.32, < 0.001), liver failure (MD = 0.44, 95% CI = 0.23-0.66, < 0.001), liver cirrhosis (MD = 1.83, 95% CI = 1.15-2.51, < 0.001), and chronic active hepatitis B (MD = 18.95, 95% CI = 10.91-27.00, < 0.001); serum galectin-9 level was significantly higher in HCC (MD = 3.74, 95% CI = 2.57-4.91, < 0.001) and autoimmune hepatitis (MD = 8.80, 95% CI = 7.61-9.99, < 0.001). High galectin-1 and -3 and low galectin-4 and -9 expression indicate worse outcomes of patients with HCC. Serum galectin-3 and -9 levels are positively associated with the risk of chronic liver diseases.
半乳糖凝集素是一类β-半乳糖苷结合蛋白，与多种人类疾病如癌症、心力衰竭和慢性肾病的发生发展相关。然而，其在肝脏疾病中的作用尚不清楚。我们检索了PubMed、Embase和Cochrane图书馆数据库。采用随机效应模型汇总风险比（HRs）、优势比（ORs）和95%置信区间的平均差（MDs），以评估半乳糖凝集素与肝脏疾病的结局和风险之间的关联。纳入了33项研究，涉及43个队列和4168例肝脏疾病患者。在肝细胞癌（HCC）患者中，组织中半乳糖凝集素-1和-3的高表达与较差的总生存期显著相关（半乳糖凝集素-1：HR = 1.94，95% CI = 1.61 - 2.34，< 0.001；半乳糖凝集素-3：HR = 3.29，95% CI = 1.62 - 6.68，< 0.001）以及血管侵犯阳性（半乳糖凝集素-1：OR = 1.74，95% CI = 1.18 - 2.58，= 0.005；半乳糖凝集素-3：OR = 2.98，95% CI = 1.58 - 5.60，= 0.001）；但是，组织中半乳糖凝集素-4和-9的高表达与较好的总生存期显著相关（半乳糖凝集素-4：HR = 0.53，95% CI = 0.36 - 0.79，= 0.002；半乳糖凝集素-9：HR = 0.56，95% CI = 0.44 - 0.71，< 0.001）以及血管侵犯阴性（半乳糖凝集素-4：OR = 0.36，95% CI = 0.19 - 0.72，= 0.003；半乳糖凝集素-9：OR = 0.60，95% CI = 0.37 - 0.97，= 0.037）。HCC（MD = 3.06，95% CI = 1.79 - 4.32，< 0.001）、肝衰竭（MD = 0.44，95% CI = 0.23 - 0.66，< 0.001）、肝硬化（MD = 1.83，95% CI = 1.15 - 2.51，< 0.001）和慢性活动性乙型肝炎（MD = 18.95，95% CI = 10.91 - 27.00，< 0.001）患者的血清半乳糖凝集素-3水平显著更高；HCC（MD = 3.74，95% CI = 2.57 - 4.91，< 0.001）和自身免疫性肝炎（MD = 8.80，95% CI = 7.61 - 9.99，< 0.001）患者的血清半乳糖凝集素-9水平显著更高。半乳糖凝集素-1和-3高表达以及半乳糖凝集素-4和-9低表达表明HCC患者的预后较差。血清半乳糖凝集素-3和-9水平与慢性肝病风险呈正相关。
Zotero 插件